CD274 and non-small cell lung carcinoma: We further examined use of first-line ICI treatment by PD-L1 expression status by NSCLC histologic type associated with the May 2017 accelerated approval for pembrolizumab in combination with chemotherapy for advanced nonsquamous NSCLC without restriction by PD-L1 status.